From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.06
First Reported 2006
Last Reported 2009
Negated 1
Speculated 0
Reported most in Body
Documents 2
Total Number 2
Disease Relevance 0.84
Pain Relevance 0.17

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytoplasm (AR, SRD5A1) cell differentiation (SRD5A1) nucleoplasm (AR)
transport (AR) small molecule metabolic process (SRD5A1) endoplasmic reticulum (SRD5A1)
AR (Homo sapiens)
SRD5A1 (Homo sapiens)
Pain Link Frequency Relevance Heat
antagonist 27 73.96 Quite High
Pyramidal cell 1 67.68 Quite High
cerebral cortex 1 66.16 Quite High
Bile 1 63.52 Quite High
depression 24 50.00 Quite Low
headache 1 15.24 Low Low
corticosteroid 1 5.00 Very Low Very Low Very Low
Paracetamol 1 5.00 Very Low Very Low Very Low
gABA 1 5.00 Very Low Very Low Very Low
Onset of action 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Benign Prostatic Hypertrophy 104 98.96 Very High Very High Very High
Reprotox - General 3 5 92.84 High High
Pressure Volume 2 Under Development 4 83.24 Quite High
Reprotox - General 1 14 79.44 Quite High
Anxiety Disorder 20 73.12 Quite High
Lower Urinary Tract Symptoms 44 69.92 Quite High
Diuresis 8 53.92 Quite High
Depression 35 50.00 Quite Low
Asthenia 2 17.92 Low Low
Dizziness 2 17.40 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The first of these to be approved for use by the FDA for treatment of BPH was finasteride, a potent competitive inhibitor of 5-alpha-reductase that shows no affinity for the androgen receptor.32 This drug inhibits the type 2 isoenzyme of 5-alpha-reductase, which is present at high levels in the prostate.
androgen receptor Neg (no) Binding (affinity) of 5-alpha-reductase associated with benign prostatic hypertrophy
1) Confidence 0.06 Published 2009 Journal Patient Prefer Adherence Section Body Doc Link PMC2778433 Disease Relevance 0.31 Pain Relevance 0.07
Testosterone, the main androgenic hormone, is converted by 5alpha-reductase to DHT in many tissues, which binds much more avidly with androgen receptor.
androgen receptor Binding (binds) of 5alpha-reductase
2) Confidence 0.01 Published 2006 Journal BMC Clin Pharmacol Section Body Doc Link PMC1622749 Disease Relevance 0.53 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools